Abstract Library

#2880 177-Lu-DOTATATE in 200 Patients with Neuroendocrine Tumors: Real-World Data from the SEPTRALU Registry

Introduction: Patients with neuroendocrine tumors have few treatment options after progression to first-line somatostatin analogues.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Carmona Bayonas A

Authors: Carmona-Bayonas A, Mitjavila Casanovas M, Belló P, Percovich J, Prieto A,

Keywords: PRRT, 177Lu-DOTATATE, radionuclide,

#2869 Sunitinib in Combination with Lanreotide for the Treatment of Pancreatic Neuroendocrine Tumors

Introduction: A 33-year-old patient with pancreatic neuroendocrine tumor (NET) G2 revealed progression of the disease in the form of multiple metastases to the liver, lymph nodes of the hepatoduodenal ligament and retroperitoneal space 1.5 months after surgical treatment.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Markovich A, Kuznetsova A, Emelianova G, Dronova E,

Keywords: neuroendocrine tumor, pancreas, sunitinib, somatostatin analogues,

#2835 Primary Hepatic Neuroendocrine Carcinoma: Case Report and Literature Review

Introduction: Primary hepatic neuroendocrine carcinoma (PHNEC) is an extremely rare neuroendocrine carcinoma (NEC) that originate from the liver. The diagnosis of PHNEC remains challenging because of its rarity, and its lack of unique clinical features. Available treatment options for PHNEC include surgical resection of the liver tumor(s), radiotherapy, liver transplant, transcatheter arterial chemoembolization (TACE), and administration of somatostatin analogues.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Saidi M, Ghomari S,

Keywords: primary hepatic neuroendocrine carcinoma, liver biopsy, immunohistochemical staining, Somatostatin analogue,

#2298 Large Cell Neuroendocrine Carcinoma of the Lung with Atypical Evolution and Great Response to Innovative Treatments

Introduction: Pulmonary neuroendocrine tumors are a group of heterogeneous neoplasms that represent 1% to 2% of all lung cancers.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Escala Cornejo R

Authors: Escala Cornejo R, Navarro M, García-Talavera SanMiguel P, Pérez López B, García Muñoz M,

Keywords: LCNEC,

#1238 Use of Everolimus in a Patient with Metastatic Bronchial Carcinoid Receiving Hemodialysis.

Introduction: Renal impairment may alter the normal pharmacokinetic and pharmacodynamic behavior of chemotherapy drugs, thus increasing the risk of side effects. Everolimus was reported to have anti-tumor activity in bronchial neuroendocrine tumors (NET). Safety and toxicity profile of everolimus has been provided in hemodialyzed patients with renal cell carcinoma. Only a report describes the effect of everolimus in a patient with metastatic ileac carcinoid in hemodialysis.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Brizzi M, Sonetto C, Bitossi R, Baratelli C, Volante M,

Keywords: Bronchial carcinoid, everolimus, hemodialysis,